A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma

Robert Z. Orlowski, Liana Gercheva, Cathy Williams, Heather Sutherland, Tadeusz Robak, T. Masszi, Vesselina Goranova-Marinova, Meletios A. Dimopoulos, James D. Cavenagh, Ivan Špička, Angelo Maiolino, Alexander Suvorov, Joan Bladé, Olga Samoylova, Thomas A. Puchalski, Manjula Reddy, Rajesh Bandekar, Helgi van de Velde, Hong Xie, Jean Franois Rossi

Research output: Article

70 Citations (Scopus)

Abstract

We compared the safety and efficacy of siltuximab (S), an anti-interleukin-6 chimeric monoclonal antibody, plus bortezomib (B) with placebo (plc) + B in patients with relapsed/refractory multiple myeloma in a randomized phase 2 study. Siltuximab was given by 6 mg/kg IV every 2 weeks. On progression, B was discontinued and high-dose dexamethasone could be added to S/plc. Response and progression-free survival (PFS) were analyzed pre-dexamethasone by European Group for Blood and Marrow Transplantation (EBMT) criteria. For the 281 randomized patients, median PFS for S + B and plc + B was 8.0 and 7.6 months (HR 0.869, P = 0.345), overall response rate was 55 versus 47% (P = 0.213), complete response rate was 11 versus 7%, and median overall survival (OS) was 30.8 versus 36.8 months (HR 1.353, P = 0.103). Sustained suppression of C-reactive protein, a marker reflective of inhibition of interleukin-6 activity, was seen with S + B. Siltuximab did not affect B pharmacokinetics. Siltuximab/placebo discontinuation (75 versus 66%), grade ≥3 neutropenia (49 versus 29%), thrombocytopenia (48 versus 34%), and all-grade infections (62 versus 49%) occurred more frequently with S + B. The addition of siltuximab to bortezomib did not appear to improve PFS or OS despite a numerical increase in response rate in patients with relapsed or refractory multiple myeloma.

Original languageEnglish
Pages (from-to)42-49
Number of pages8
JournalAmerican Journal of Hematology
Volume90
Issue number1
DOIs
Publication statusPublished - jan. 1 2015

Fingerprint

Multiple Myeloma
Interleukin-6
Placebos
Disease-Free Survival
Dexamethasone
Survival
Neutropenia
Thrombocytopenia
C-Reactive Protein
Pharmacokinetics
Monoclonal Antibodies
siltuximab
Bortezomib
Safety
Infection

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. / Orlowski, Robert Z.; Gercheva, Liana; Williams, Cathy; Sutherland, Heather; Robak, Tadeusz; Masszi, T.; Goranova-Marinova, Vesselina; Dimopoulos, Meletios A.; Cavenagh, James D.; Špička, Ivan; Maiolino, Angelo; Suvorov, Alexander; Bladé, Joan; Samoylova, Olga; Puchalski, Thomas A.; Reddy, Manjula; Bandekar, Rajesh; van de Velde, Helgi; Xie, Hong; Rossi, Jean Franois.

In: American Journal of Hematology, Vol. 90, No. 1, 01.01.2015, p. 42-49.

Research output: Article

Orlowski, RZ, Gercheva, L, Williams, C, Sutherland, H, Robak, T, Masszi, T, Goranova-Marinova, V, Dimopoulos, MA, Cavenagh, JD, Špička, I, Maiolino, A, Suvorov, A, Bladé, J, Samoylova, O, Puchalski, TA, Reddy, M, Bandekar, R, van de Velde, H, Xie, H & Rossi, JF 2015, 'A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma', American Journal of Hematology, vol. 90, no. 1, pp. 42-49. https://doi.org/10.1002/ajh.23868
Orlowski, Robert Z. ; Gercheva, Liana ; Williams, Cathy ; Sutherland, Heather ; Robak, Tadeusz ; Masszi, T. ; Goranova-Marinova, Vesselina ; Dimopoulos, Meletios A. ; Cavenagh, James D. ; Špička, Ivan ; Maiolino, Angelo ; Suvorov, Alexander ; Bladé, Joan ; Samoylova, Olga ; Puchalski, Thomas A. ; Reddy, Manjula ; Bandekar, Rajesh ; van de Velde, Helgi ; Xie, Hong ; Rossi, Jean Franois. / A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. In: American Journal of Hematology. 2015 ; Vol. 90, No. 1. pp. 42-49.
@article{bfc273b369864dd0ae47e8d620b0d6e1,
title = "A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma",
abstract = "We compared the safety and efficacy of siltuximab (S), an anti-interleukin-6 chimeric monoclonal antibody, plus bortezomib (B) with placebo (plc) + B in patients with relapsed/refractory multiple myeloma in a randomized phase 2 study. Siltuximab was given by 6 mg/kg IV every 2 weeks. On progression, B was discontinued and high-dose dexamethasone could be added to S/plc. Response and progression-free survival (PFS) were analyzed pre-dexamethasone by European Group for Blood and Marrow Transplantation (EBMT) criteria. For the 281 randomized patients, median PFS for S + B and plc + B was 8.0 and 7.6 months (HR 0.869, P = 0.345), overall response rate was 55 versus 47{\%} (P = 0.213), complete response rate was 11 versus 7{\%}, and median overall survival (OS) was 30.8 versus 36.8 months (HR 1.353, P = 0.103). Sustained suppression of C-reactive protein, a marker reflective of inhibition of interleukin-6 activity, was seen with S + B. Siltuximab did not affect B pharmacokinetics. Siltuximab/placebo discontinuation (75 versus 66{\%}), grade ≥3 neutropenia (49 versus 29{\%}), thrombocytopenia (48 versus 34{\%}), and all-grade infections (62 versus 49{\%}) occurred more frequently with S + B. The addition of siltuximab to bortezomib did not appear to improve PFS or OS despite a numerical increase in response rate in patients with relapsed or refractory multiple myeloma.",
author = "Orlowski, {Robert Z.} and Liana Gercheva and Cathy Williams and Heather Sutherland and Tadeusz Robak and T. Masszi and Vesselina Goranova-Marinova and Dimopoulos, {Meletios A.} and Cavenagh, {James D.} and Ivan Špička and Angelo Maiolino and Alexander Suvorov and Joan Blad{\'e} and Olga Samoylova and Puchalski, {Thomas A.} and Manjula Reddy and Rajesh Bandekar and {van de Velde}, Helgi and Hong Xie and Rossi, {Jean Franois}",
year = "2015",
month = "1",
day = "1",
doi = "10.1002/ajh.23868",
language = "English",
volume = "90",
pages = "42--49",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma

AU - Orlowski, Robert Z.

AU - Gercheva, Liana

AU - Williams, Cathy

AU - Sutherland, Heather

AU - Robak, Tadeusz

AU - Masszi, T.

AU - Goranova-Marinova, Vesselina

AU - Dimopoulos, Meletios A.

AU - Cavenagh, James D.

AU - Špička, Ivan

AU - Maiolino, Angelo

AU - Suvorov, Alexander

AU - Bladé, Joan

AU - Samoylova, Olga

AU - Puchalski, Thomas A.

AU - Reddy, Manjula

AU - Bandekar, Rajesh

AU - van de Velde, Helgi

AU - Xie, Hong

AU - Rossi, Jean Franois

PY - 2015/1/1

Y1 - 2015/1/1

N2 - We compared the safety and efficacy of siltuximab (S), an anti-interleukin-6 chimeric monoclonal antibody, plus bortezomib (B) with placebo (plc) + B in patients with relapsed/refractory multiple myeloma in a randomized phase 2 study. Siltuximab was given by 6 mg/kg IV every 2 weeks. On progression, B was discontinued and high-dose dexamethasone could be added to S/plc. Response and progression-free survival (PFS) were analyzed pre-dexamethasone by European Group for Blood and Marrow Transplantation (EBMT) criteria. For the 281 randomized patients, median PFS for S + B and plc + B was 8.0 and 7.6 months (HR 0.869, P = 0.345), overall response rate was 55 versus 47% (P = 0.213), complete response rate was 11 versus 7%, and median overall survival (OS) was 30.8 versus 36.8 months (HR 1.353, P = 0.103). Sustained suppression of C-reactive protein, a marker reflective of inhibition of interleukin-6 activity, was seen with S + B. Siltuximab did not affect B pharmacokinetics. Siltuximab/placebo discontinuation (75 versus 66%), grade ≥3 neutropenia (49 versus 29%), thrombocytopenia (48 versus 34%), and all-grade infections (62 versus 49%) occurred more frequently with S + B. The addition of siltuximab to bortezomib did not appear to improve PFS or OS despite a numerical increase in response rate in patients with relapsed or refractory multiple myeloma.

AB - We compared the safety and efficacy of siltuximab (S), an anti-interleukin-6 chimeric monoclonal antibody, plus bortezomib (B) with placebo (plc) + B in patients with relapsed/refractory multiple myeloma in a randomized phase 2 study. Siltuximab was given by 6 mg/kg IV every 2 weeks. On progression, B was discontinued and high-dose dexamethasone could be added to S/plc. Response and progression-free survival (PFS) were analyzed pre-dexamethasone by European Group for Blood and Marrow Transplantation (EBMT) criteria. For the 281 randomized patients, median PFS for S + B and plc + B was 8.0 and 7.6 months (HR 0.869, P = 0.345), overall response rate was 55 versus 47% (P = 0.213), complete response rate was 11 versus 7%, and median overall survival (OS) was 30.8 versus 36.8 months (HR 1.353, P = 0.103). Sustained suppression of C-reactive protein, a marker reflective of inhibition of interleukin-6 activity, was seen with S + B. Siltuximab did not affect B pharmacokinetics. Siltuximab/placebo discontinuation (75 versus 66%), grade ≥3 neutropenia (49 versus 29%), thrombocytopenia (48 versus 34%), and all-grade infections (62 versus 49%) occurred more frequently with S + B. The addition of siltuximab to bortezomib did not appear to improve PFS or OS despite a numerical increase in response rate in patients with relapsed or refractory multiple myeloma.

UR - http://www.scopus.com/inward/record.url?scp=84919683208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919683208&partnerID=8YFLogxK

U2 - 10.1002/ajh.23868

DO - 10.1002/ajh.23868

M3 - Article

C2 - 25294016

AN - SCOPUS:84919683208

VL - 90

SP - 42

EP - 49

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 1

ER -